Are there any medical indications for administering testosterone to a female patient?

Medical Advisory BoardAll articles are reviewed for accuracy by our Medical Advisory Board
Educational purpose only • Exercise caution as content is pending human review
Article Review Status
Submitted
Under Review
Approved

Last updated: November 17, 2026 • View editorial policy

Have a follow-up question?

Our Medical A.I. is used by practicing medical doctors at top research institutions around the world. Ask any follow up question and get world-class guideline-backed answers instantly.

Medical Indications for Testosterone in Women

Yes, there is one evidence-based medical indication for testosterone in women: treatment of hypoactive sexual desire disorder (HSDD) in postmenopausal women after formal biopsychosocial assessment. 1

The Single Approved Indication

The 2019 Global Consensus Position Statement is unequivocal: the only evidence-based indication for testosterone use in women is for postmenopausal women diagnosed with HSDD following comprehensive biopsychosocial evaluation (Level I, Grade A evidence). 1 This represents the highest quality recommendation based on randomized controlled trials showing moderate therapeutic benefit for sexual desire, arousal, and satisfaction.

The 2014 Endocrine Society guideline reinforces this position, explicitly recommending against generalized testosterone use for infertility, cognitive dysfunction, cardiovascular health, metabolic dysfunction, bone health, or general well-being—with the sole exception being HSDD. 2

What HSDD Actually Means

HSDD is not simply "low libido." It requires:

  • Persistent or recurrent deficiency in sexual desire causing personal distress
  • Absence of other identifiable causes including relationship problems, psychological distress, medications, or physical illness
  • Formal biopsychosocial assessment ruling out modifiable factors 1

This is critical: you cannot simply prescribe testosterone because a woman reports decreased sexual desire. The evaluation must exclude depression, relationship discord, medication side effects (SSRIs are notorious), inadequate stimulation, body image issues, history of sexual trauma, and other medical conditions.

Limited Evidence for Premenopausal Women

While the strongest evidence supports use in postmenopausal women, limited data suggest potential benefit in late reproductive age premenopausal women with HSDD 3. However, this remains off-label with less robust safety data, and the 2014 Endocrine Society guideline recommends against routine treatment in premenopausal women due to insufficient evidence. 2

What Testosterone Does NOT Treat in Women

The evidence explicitly contradicts testosterone use for:

  • Bone health: No recommendation despite theoretical rationale 2
  • Cognitive function: Insufficient data 4
  • Energy or fatigue: Not supported 5
  • General well-being: No clear indication 2
  • Breast cancer prevention: No data 1
  • Cardiovascular protection: Insufficient evidence 1
  • Infertility: Not recommended 2

Critical Prescribing Requirements

If you prescribe testosterone for HSDD:

Before Starting

  • Obtain baseline total testosterone level—not to diagnose HSDD (testosterone levels don't correlate with symptoms), but to monitor for supraphysiologic dosing 1
  • Provide informed consent discussing off-label use, lack of FDA-approved female formulations, limited long-term safety data beyond 24 months 1, 3
  • Document biopsychosocial assessment ruling out other causes

Formulation and Dosing

  • Use transdermal preparations (patches, gels, creams)—NOT oral formulations due to adverse hepatic effects 1
  • Avoid pellets and injections—these cause supraphysiologic levels 1
  • Off-label use of male formulations is acceptable if dosed to maintain physiologic female premenopausal range 1
  • Compounded "bioidentical" products cannot be recommended due to lack of efficacy and safety data, unless no approved alternative exists 1

Monitoring Protocol

  • Recheck testosterone at 3-6 weeks after initiation 1
  • Monitor every 6 months for clinical response and signs of androgen excess (acne, hirsutism, voice deepening) 1
  • Discontinue if no benefit by 6 months 1
  • Maintain testosterone in physiologic premenopausal range (not supraphysiologic) 1

Safety Profile

Short-term safety data (up to 24 months) are reassuring:

  • No increase in serious adverse events at physiologic doses 1
  • No increase in mammographic breast density 1
  • No impact on short-term breast cancer risk 1
  • No adverse effects on lipids, blood pressure, glucose, or HbA1c 1
  • Mild, reversible androgenic effects (acne, hirsutism) are most common 1

Critical Safety Gaps

  • Long-term safety beyond 24 months is unknown 1
  • Most trials excluded high cardiovascular risk women and included concurrent estrogen therapy, limiting generalizability 1
  • Long-term breast cancer risk is not established 1

Contraindications

Exercise caution or avoid in:

  • Hormone-sensitive breast cancer (women with prior breast cancer were excluded from trials) 1
  • High cardiometabolic risk (not studied in this population) 1
  • Cardiovascular or liver disease 6

The Regulatory Reality

No FDA-approved testosterone formulation exists for women in the United States 5, 3. This creates a significant access problem, forcing clinicians to use off-label male formulations or compounded products of variable quality. Despite decades of use globally and consistent evidence of moderate benefit for HSDD, regulatory approval remains elusive due to lack of long-term safety data. 5, 7

Common Pitfalls to Avoid

  1. Don't diagnose "androgen deficiency syndrome"—this is not a recognized clinical entity in women 2
  2. Don't use testosterone levels to diagnose HSDD—symptoms don't correlate with serum levels 2
  3. Don't prescribe for vague complaints like fatigue or "low energy" without proper HSDD diagnosis
  4. Don't use supraphysiologic doses—pellets and injections typically cause excessive levels 1
  5. Don't forget the biopsychosocial assessment—relationship therapy or psychotherapy may be more appropriate 1

DHEA Is Not the Answer

Systemic DHEA does not improve libido or sexual function in postmenopausal women with normal adrenal function and cannot be recommended for HSDD (Level IA, Grade A evidence). 1, 2 Vaginal DHEA is FDA-approved for genitourinary syndrome of menopause (vulvovaginal atrophy), not HSDD. 4

Professional Medical Disclaimer

This information is intended for healthcare professionals. Any medical decision-making should rely on clinical judgment and independently verified information. The content provided herein does not replace professional discretion and should be considered supplementary to established clinical guidelines. Healthcare providers should verify all information against primary literature and current practice standards before application in patient care. Dr.Oracle assumes no liability for clinical decisions based on this content.